Back to News
Market Impact: 0.25
Orvida Pharma Announces Interim Financing Led by Recordati to Advance Ontivatrep Development for Rare Genetic Skin Diseases
Source: GlobeNewswire
Healthcare & BiotechCompany Fundamentals
Proceeds from an unspecified financing will support continued clinical development of ontivatrep, an oral TRPV3 inhibitor. The company expects Phase 1b topline data in Olmsted syndrome by the end of 2026, providing a defined near-term clinical catalyst.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
More News
- Exclusive-Malaysia talks to rival airlines as it monitors AirAsia’s financial health, sources say
- Australia’s Reliance Worldwide agrees to Brookfield’s $2.9 billion buyout bid
- Trip.com swings to Q2 loss after $763 million antitrust penalty
- Wells Fargo sees improvement in a key metric — plus, Lilly gets praise beyond GLP-1s
- Reliance Worldwide shares hit 1-year high on Brookfield’s $2.9 bln deal
- Why Dave & Buster's Stock Tumbled Today